Ideaya Biosciences Net Income
| IDYA Stock | USD 32.99 0.66 1.96% |
As of the 30th of January, Ideaya Biosciences retains the Market Risk Adjusted Performance of 0.2593, risk adjusted performance of 0.0665, and Downside Deviation of 2.18. Ideaya Biosciences technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Ideaya Biosciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 10.1914 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -247 M | -234.7 M | |
| Net Loss | -52.8 M | -55.4 M | |
| Net Loss | -247 M | -234.7 M | |
| Net Loss | (3.86) | (4.06) |
Ideaya | Net Income | Build AI portfolio with Ideaya Stock |
Analyzing Ideaya Biosciences's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Ideaya Biosciences's current valuation and future prospects.
Latest Ideaya Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Ideaya Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Ideaya Biosciences financial statement analysis. It represents the amount of money remaining after all of Ideaya Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Ideaya Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ideaya Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (274.48 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Ideaya Net Income Regression Statistics
| Arithmetic Mean | (68,907,831) | |
| Coefficient Of Variation | (132.59) | |
| Mean Deviation | 69,825,154 | |
| Median | (32,265,000) | |
| Standard Deviation | 91,365,095 | |
| Sample Variance | 8347.6T | |
| Range | 262.6M | |
| R-Value | (0.79) | |
| Mean Square Error | 3300.6T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | (14,353,088) | |
| Total Sum of Squares | 133561.3T |
Ideaya Net Income History
Other Fundumenentals of Ideaya Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Ideaya Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Ideaya Biosciences is extremely important. It helps to project a fair market value of Ideaya Stock properly, considering its historical fundamentals such as Net Income. Since Ideaya Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ideaya Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ideaya Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. Market participants price Ideaya higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ideaya Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.89) | Revenue Per Share | Quarterly Revenue Growth 0.785 | Return On Assets | Return On Equity |
The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Ideaya Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Ideaya Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ideaya Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ideaya Biosciences.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Ideaya Biosciences on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Ideaya Biosciences or generate 0.0% return on investment in Ideaya Biosciences over 90 days. Ideaya Biosciences is related to or competes with Scholar Rock, Mineralys Therapeutics, Zai Lab, Beam Therapeutics, Adaptive Biotechnologies, Amicus Therapeutics, and Kiniksa Pharmaceuticals. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery an... More
Ideaya Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ideaya Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ideaya Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.18 | |||
| Information Ratio | 0.059 | |||
| Maximum Drawdown | 15.68 | |||
| Value At Risk | (3.68) | |||
| Potential Upside | 4.86 |
Ideaya Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ideaya Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ideaya Biosciences' standard deviation. In reality, there are many statistical measures that can use Ideaya Biosciences historical prices to predict the future Ideaya Biosciences' volatility.| Risk Adjusted Performance | 0.0665 | |||
| Jensen Alpha | 0.1683 | |||
| Total Risk Alpha | 0.0195 | |||
| Sortino Ratio | 0.0737 | |||
| Treynor Ratio | 0.2493 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ideaya Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Ideaya Biosciences January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0665 | |||
| Market Risk Adjusted Performance | 0.2593 | |||
| Mean Deviation | 2.06 | |||
| Semi Deviation | 2.03 | |||
| Downside Deviation | 2.18 | |||
| Coefficient Of Variation | 1227.26 | |||
| Standard Deviation | 2.72 | |||
| Variance | 7.42 | |||
| Information Ratio | 0.059 | |||
| Jensen Alpha | 0.1683 | |||
| Total Risk Alpha | 0.0195 | |||
| Sortino Ratio | 0.0737 | |||
| Treynor Ratio | 0.2493 | |||
| Maximum Drawdown | 15.68 | |||
| Value At Risk | (3.68) | |||
| Potential Upside | 4.86 | |||
| Downside Variance | 4.75 | |||
| Semi Variance | 4.13 | |||
| Expected Short fall | (2.41) | |||
| Skewness | 1.05 | |||
| Kurtosis | 2.55 |
Ideaya Biosciences Backtested Returns
At this point, Ideaya Biosciences is very steady. Ideaya Biosciences holds Efficiency (Sharpe) Ratio of 0.0468, which attests that the entity had a 0.0468 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Ideaya Biosciences, which you can use to evaluate the volatility of the firm. Please check out Ideaya Biosciences' Risk Adjusted Performance of 0.0665, market risk adjusted performance of 0.2593, and Downside Deviation of 2.18 to validate if the risk estimate we provide is consistent with the expected return of 0.11%. Ideaya Biosciences has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.85, which attests to possible diversification benefits within a given portfolio. Ideaya Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Ideaya Biosciences is expected to follow. Ideaya Biosciences right now retains a risk of 2.41%. Please check out Ideaya Biosciences downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to decide if Ideaya Biosciences will be following its current trending patterns.
Auto-correlation | 0.55 |
Modest predictability
Ideaya Biosciences has modest predictability. Overlapping area represents the amount of predictability between Ideaya Biosciences time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ideaya Biosciences price movement. The serial correlation of 0.55 indicates that about 55.0% of current Ideaya Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.55 | |
| Spearman Rank Test | 0.19 | |
| Residual Average | 0.0 | |
| Price Variance | 1.53 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Ideaya Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Ideaya Biosciences reported net income of (274.48 Million). This is 180.43% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 148.07% higher than that of the company.
Ideaya Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ideaya Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ideaya Biosciences could also be used in its relative valuation, which is a method of valuing Ideaya Biosciences by comparing valuation metrics of similar companies.Ideaya Biosciences is currently under evaluation in net income category among its peers.
Ideaya Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ideaya Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ideaya Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Ideaya Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Ideaya Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ideaya Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ideaya Biosciences' value.| Shares | Baker Bros Advisors Lp | 2025-06-30 | 2.1 M | Geode Capital Management, Llc | 2025-06-30 | 2.1 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 1.9 M | Citadel Advisors Llc | 2025-06-30 | 1.8 M | Pictet Asset Manangement Sa | 2025-06-30 | 1.8 M | Fiera Capital Corporation | 2025-06-30 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.5 M | Adage Capital Partners Gp Llc | 2025-06-30 | 1.2 M | Goldman Sachs Group Inc | 2025-06-30 | 1.2 M | Fmr Inc | 2025-06-30 | 13.1 M | Blackrock Inc | 2025-06-30 | 8.8 M |
Ideaya Fundamentals
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.75) % | ||||
| Operating Margin | 0.52 % | ||||
| Current Valuation | 2.19 B | ||||
| Shares Outstanding | 87.67 M | ||||
| Shares Owned By Insiders | 0.90 % | ||||
| Shares Owned By Institutions | 99.10 % | ||||
| Number Of Shares Shorted | 8.71 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 2.70 X | ||||
| Price To Sales | 13.46 X | ||||
| Revenue | 7 M | ||||
| Gross Profit | (153.45 M) | ||||
| EBITDA | (270.64 M) | ||||
| Net Income | (274.48 M) | ||||
| Cash And Equivalents | 268.62 M | ||||
| Cash Per Share | 6.83 X | ||||
| Total Debt | 19.17 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.69 X | ||||
| Book Value Per Share | 12.46 X | ||||
| Cash Flow From Operations | (247.58 M) | ||||
| Short Ratio | 9.05 X | ||||
| Earnings Per Share | (1.89) X | ||||
| Target Price | 49.94 | ||||
| Number Of Employees | 131 | ||||
| Beta | 0.05 | ||||
| Market Capitalization | 2.89 B | ||||
| Total Asset | 1.12 B | ||||
| Retained Earnings | (622.84 M) | ||||
| Working Capital | 643.64 M | ||||
| Current Asset | 93.24 M | ||||
| Current Liabilities | 6.51 M | ||||
| Net Asset | 1.12 B |
About Ideaya Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ideaya Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ideaya Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ideaya Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. Market participants price Ideaya higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ideaya Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.89) | Revenue Per Share | Quarterly Revenue Growth 0.785 | Return On Assets | Return On Equity |
The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Ideaya Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.